Latest:
Dr Mok on the Efficacy of Taletrectinib in ROS1+ NSCLC
Tony S. K. Mok, BMSc, MD, FASCO, discusses efficacy findings from a pooled analysis of the TRUST-I and TRUST-II trials of taletrectinib in ROS1+ NSCLC.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Tony S. K. Mok, MD, BMSc, FRCPC, FASCO
Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, is chairman of the Department of Clinical Oncology and the Li Shu Fan Professor of Clinical Oncology at the Chinese University of Hong Kong
Latest:
Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC
Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, shares final OS data from the phase 3 ALEX study in ALK-positive NSCLC.
Toshiaki Iwase, MD
Latest:
Dr. Iwase on Elevated Neutrophil to Lymphocyte Ratio to Predict Survival Outcome in TNBC
Toshiaki Iwase, MD, Department of General Surgery, Chiba Graduate School of Medicine, Chiba, Japan, discusses a study that examined elevated neutrophil to lymphocyte ratio to predict survival outcomes after recurrence in patients with triple-negative breast cancer.
Tracey L. O’Connor, MD
Latest:
Discussing Palliative Care Plans Earlier Improves Quality of Life
A team of researchers take a retrospective look at the patterns of how, when, and to whom palliative options are presented to patients with metastatic breast cancer, as an approach for gaining insight on how to improve care for patients with late-stage, terminal cancers.
Tracey Regan
Latest:
Blackwell Explores Emerging Trends in Treating HER2 Metastatic Breast Cancer
Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.
Traci L. Hedrick, MD, MS
Latest:
Enhanced Recovery Program Improves Outcomes After Colorectal Cancer Surgery
The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.